Early Long-Acting Injectables in Schizophrenia: A Manufacturer-Funded Narrative Case
This narrative review argues for repositioning long-acting injectable antipsychotics as first-line therapy within the first 5 years of schizophrenia, a stance relevant to ambulatory adherence and relapse-prevention workflows.
📅 Journal publication: Jul 2026(online May 27, 2026)·Last updated: Oct 5, 2026
Early LAI use in schizophrenia improves outcomes and adherence.
Early intervention with long-acting injectable (LAI) antipsychotics in schizophrenia could improve outcomes significantly. LAIs used early in treatment show reduced relapse rates and lower healthcare costs. Encourages first-line use of LAIs, yet notes current underuse and need for improved clinical adoption. Consider LAIs early in schizophrenia for better adherence and outcomes.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Citation:Harrison SJ, Antunes J, Knight K, et al. The Role of Long-Acting Injectable Antipsychotics in the Early Treatment of Schizophrenia. CNS drugs. 2026;40(7):921-948. doi:10.1007/s40263-026-01294-9